biopharma clusters 21.1.2013

21
This project is funded by the European Union Integrated Innovation Support Programme Best Practice in Biopharma Clusters and Initiatives Dr. Yannis Pierrakis, 21 Jan 2013

Upload: iisp-srbija

Post on 11-May-2015

154 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Integrated Innovation Support

Programme

Best Practice in Biopharma Clusters and

Initiatives

Dr. Yannis Pierrakis, 21 Jan 2013

Page 2: Biopharma clusters 21.1.2013

This project is funded by

the European Union Structure of the presentation

• Current Trends on Biopharma Clusters

• Clusters, data and the internet

• Case study 1: OneNucleus – Cambridge

• Case study 2: Bavarian Biotechnology Cluster

• Common features within the success stories

– How do they operate?

– How do they secure finance?

• EBR Council of European BioRegions

• Useful links

2

Page 3: Biopharma clusters 21.1.2013

This project is funded by

the European Union Current Trends on Biopharma Clusters

• Companies and clusters form strategic alliances

– High uncertainty of product outcome and a heavy

reliance on R&D

– Companies are becoming increasingly unable to

conduct complete in-house R&D development

– We are seeing a growing number of strategic alliances

between pharmaceutical companies, biotechs,

academic centres and clusters

– 2800 European organisations are currenlty active in

the biopharmaceutical industry, 1050 are actively

engaging in strategic alliances with others (PharmaDeals 2006)

3

Page 4: Biopharma clusters 21.1.2013

This project is funded by

the European Union Current Trends on Biopharma Clusters

Integrated Innovation

Support Programme (IISP) 4

Source: PharmaDeals 2006

Page 5: Biopharma clusters 21.1.2013

This project is funded by

the European Union Leveraging efforts and resources

5

Page 6: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Clusters, data and the internet

6

Page 7: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Clusters, data and the internet

7

Page 8: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

8

- Not for profit organisation

- A large pool of companies to support

business-to-business interaction

- Membership provides discounted entry to

events in London and Cambridge

- Economies of scale supporting the

group’s purchasing scheme

- An expanded training programme

focused on the needs of members

- Investment pitches

- Well connected with Universities and VCs

Page 9: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

9

- Training courses (for managers and scientists,

50% subsidized for SMEs, innovation vouchers)

- Small Molecule Drug Discovery

- Introduction to Drug Development

- Introduction to Management

- Health and Safety for Representatives and

Managers

- Laboratory Health and Safety

- Commercial Awareness

- Scientific Presentation Skills

- BioProject Management

Page 10: Biopharma clusters 21.1.2013

This project is funded by

the European Union OneNucleus – Cambridge

10

- Services and activities

- Collaborates with Cambridge University to

allow its Members to attend a series of

lectures on Management of Technology and

Innovation

- Available lab space

- Equipment/items for sale (including auctions

from around the world)

- Relationships with US top clusters

- Participates in EU funded projects

- Collaboration with BioMunich

Page 11: Biopharma clusters 21.1.2013

This project is funded by

the European Union 5 Reasons why Cambridge is a Success

11

1. Most important has been the presence of

Cambridge University

2. Strong local industrial base has provided the

necessary general infrastructure

3. Provision of purpose-built bio-incubator

facilities

4. The entrepreneurial culture

5. The availability of venture capital funding

from London

Page 12: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Cluster’s objectives:

– Development of an innovation culture from education

to economy

– Supporting connections within the biotechindustry

itself as well as between local biotech companies and

global players

– Strengthening ties between research institutions and

the industry

– Advice on finance opportunities and promotion

schemes and funding programs

– Representation at the international level

12

Page 13: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Network Organisation and International Representation

– Development of synergy potentials and communicates

a uniform public presence

– Preparation of an annual Bavarian-wide Biotechnology

Report

– Establishment of an interactive B@B communication

portal for the networking between research and

industry

– Regular need-assessments for the regions's SMEs

13

Page 14: Biopharma clusters 21.1.2013

This project is funded by

the European Union Bavarian Biotechnology Cluster

• Scouting and Technology Transfer

– Targeted scouting activities enable the transfer of

innovative technologies from research institutions to

companies and provide active support for start-ups

– Active scouting for innovative research projects with

commercialisation potential

– Establishment of Cluster Scouting Groups composed

of experts from the academic community and the

industry

– Coaching and training

14

Page 15: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Key driving forces of pharma/biotech

cluster

15

Page 16: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• How do they operate?

– Active networking in order to facilitate access to

knowledge, funding and equipment

– Establish collaboration with universities and

incubators

– Organise training based on their member’s

needs

– Form purchasing consortia, which through bulk

buying reduces the cost of laboratory material

purchases

16

Page 17: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• How do they operate?

– Facilitate access to VC funding

– Cluster promotion (attending trade

fairs/conferences, organising conferences,

partnering events with overseas companies,

presentations for local companies)

– Articulate needs/lobbying (interaction with local

government, interaction with national

government)

17

Page 18: Biopharma clusters 21.1.2013

This project is funded by

the European Union

Common features within the success

stories

• From where do cluster organisations finance their

activities?

– Provide training at a fee (not only to cluster

members but to all interested parties)

– Subscriptions (depends on the company size e.g.

in OneNucleus starts from £165)

– Receive sponsorships (large companies,

associations)

– Activation of already existing financing schemes

– Actively involve in EU funded projects

18

Page 19: Biopharma clusters 21.1.2013

This project is funded by

the European Union EBR Council of European BioRegions

• A self-financed network with over 50 biocommunities as

members across Europe and with links into clusters

around the globe (spun out from an FP6 project)

• Implementing cluster strategy

– A practical guide to developing and implementing a

cluster development strategy

• Raising visibility of cluster research facilities

– Provides examples of promotion at cluster and

individual facility level

19

Page 20: Biopharma clusters 21.1.2013

This project is funded by

the European Union EBR Council of European BioRegions

• Internationalisation services

– Sharing the internationalisation tools commonly in use

in clusters across Europe

• SME self assessment tools

– An invaluable collection of websites that cluster

managers can use to support their SMEs in business

development

• Support for cluster actors

– Another extensive website section, with examples of

how cluster managers support different parts of their

biocommunity, with a strong focus on SME

development

20

Page 21: Biopharma clusters 21.1.2013

This project is funded by

the European Union Useful links

• European Cluster Observatory

http://www.clusterobservatory.eu

• EBR Council of European BioRegions

http://www.cebr.net

• OneNucleus

http://www.onenucleus.com

• Cambridge Cluster Map

http://www.camclustermap.com

• Bavarian Biotechnology Cluster

http://www.biotech-bavaria.de

• Bio-Munich

http://www.bio-m.org/en

21